Rockville, MD, United States of America

Elena A Cherkasova


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Elena A. Cherkasova

Introduction

Elena A. Cherkasova is a prominent inventor based in Rockville, MD (US). She has made significant contributions to the field of medical science, particularly in the development of T cell receptors for cancer treatment. Her innovative work has led to the filing of a patent that showcases her expertise and dedication to advancing healthcare solutions.

Latest Patents

Elena A. Cherkasova holds a patent for "HERV-E reactive T cell receptors and methods of use." This patent discloses T cell receptors (TCRs) capable of binding an antigen expressed by renal cell carcinoma cells. The TCRs include an α chain and a β chain, which are essential for their functionality. The patent also describes vectors that include nucleic acids encoding these TCR chains, as well as modified T cells expressing the TCRs. The methods outlined in the patent involve treating subjects with renal cell carcinoma by transducing T cells with vectors that encode the TCR chains and administering modified T cells to the patients.

Career Highlights

Throughout her career, Elena has worked with esteemed organizations such as the National Institutes of Health, a component of the US Department of Health & Human Services, and Loyola University of Chicago. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Elena has collaborated with notable colleagues, including Richard W. Childs and Michael I. Nishimura. These partnerships have further enhanced her research and innovation in the field of T cell therapy.

Conclusion

Elena A. Cherkasova's contributions to medical science through her innovative patents and collaborations highlight her role as a leading inventor in the field. Her work continues to pave the way for advancements in cancer treatment and immunotherapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…